Skip to main content

Advertisement

Whole body MR-PET: a new internal dosimetry method for radiation transport calculation from biokinetic model data

Article metrics

  • 699 Accesses

  • 1 Citations

In order to ensure the safe usage of new radiopharmaceuticals in Positron Emission Tomography (PET), it is necessary to quantify the doses delivered to the organs and tissues within the patients’ bodies. A framework that allows estimating the dose delivered by PET has been established by the MIRD Committee [1, 2] and ICRP [3]. Although this covers the most important terms and concepts in Internal Radiation Dosimetry (IRD), it does not provide a detailed guide to assist in the development of a full dosimetric study. We discuss the development, implementation, assessment and validation of an accurate method for IRD studies of PET radiotracers.

We undertook a systematic review [4, 5] of previous PET dosimetry studies to identify the current biodistribution data acquisition and analysis methodologies. The methods reported were compared, particularly in terms of the collection of biokinetic data and the estimation of dose results. As a wide heterogeneity of approaches was found, it is important to assessthe impact of different choices in the internal dose calculation protocol. In particular, we quantify the variation in internal dose with different assumptions regarding organ activity uptake - namely, instantaneous uptake vs. different methods to extrapolate to zero activity at time zero. For that purpose, whole-body 11C-Raclopride PET data have been acquired and the corresponding internal doses estimated.

References

  1. 1.

    Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, Howel RWl, Wessels BW, Fisher DR: MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J. Nucl. Med. 1999,40(2):37–61.

  2. 2.

    Bolch WE, Eckerman KF, Sgouros G, Thomas SR: MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry—standardization of nomenclature. J. Nucl. Med. 2009, 50: 477–484. 10.2967/jnumed.108.056036

  3. 3.

    ICRP: The 2007 Recommendations of the International Commission on Radiological Protection. Ann. ICRP ICRP Publication 103; 2007,37(2.4):2. [http://www.icrp.org/docs/ICRP_Publication_103-Annals_of_the_ICRP_37(2–4)-Free_extract.pdf]

  4. 4.

    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 2009.,151(4): 10.1136/bmj.b2700

  5. 5.

    Moher D, Liberat A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009, 151: 264–269. 10.7326/0003-4819-151-4-200908180-00135

Download references

Author information

Correspondence to Ana Nunes.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Positron Emission Tomography
  • Positron Emission Tomography Data
  • Internal Dose
  • Biodistribution Data
  • Calculation Protocol